Rejuvenate Bio Receives $4M in Funding
Rejuvenate Bio, a San Diego-based biotechnology company, has received a $4 million grant from the California Institute for Regenerative Medicine (CIRM). This funding will support the completion of IND-enabling activities for the development of RJB-0402, aimed at treating desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM). Led by CEO Dan Oliver and Chief Scientific Officer Noah … Read more